Atul Ltd: Brokerage Reiterates Buy, Eyes ₹8,500 Target After Gujarat Plant Tour

CHEMICALS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Atul Ltd: Brokerage Reiterates Buy, Eyes ₹8,500 Target After Gujarat Plant Tour
Overview

Analysts visited Atul Ltd's integrated complex in Gujarat, observing over 900 products across four divisions. The liquid epoxy resin plant operates at 75-80% utilization, with ECH supply robust. While US exports face tariffs, the company maintains a competitive edge in 2,4-D. R&D is strong with 18 patents filed. EPS is trimmed slightly for FY27E, but the Buy rating and ₹8,500 target price are maintained.

Brokerage analysts maintain a positive outlook on Atul Ltd, reiterating a 'Buy' rating with a target price of ₹8,500 following a visit to the company's expansive integrated complex in Atul, Gujarat. The sprawling 1,350-acre facility, established in 1947, is a manufacturing hub for over 900 products and 400 formulations across four distinct divisional zones.

During the visit, executives highlighted key operational details. The new liquid epoxy resin (LER) plant is currently operating at approximately 75-80% utilization of its debottlenecked capacity, primarily driven by domestic demand for windmill applications. Exports to the U.S. market have seen an impact due to tariffs.

Furthermore, the report notes an abundant supply of ECH (Epichlorohydrin) with new capacities coming online in Southeast Asia. Atul Ltd's integrated complex benefits from captive power plants that sufficiently meet its energy demands, including the caustic soda plant. The company also holds a competitive advantage in exporting 2,4-D to the United States.

Innovation and research are central to Atul's strategy. The company boasts an R&D team of 223 members and has filed for 18 patents, with 9 already granted. Analysts have slightly trimmed their FY27E Earnings Per Share (EPS) estimate by about 5% to account for near-term EBITDA margin pressure stemming from weaker U.S. export volumes. The EPS estimates have also been rolled over to December 2027 earnings.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.